{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:17:35Z","timestamp":1789150655449,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ejogrb.2020.05.018","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T11:36:45Z","timestamp":1589542605000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Mirabegron in female patients with overactive bladder syndrome: What\u2019s new? A systematic review and meta-analysis"],"prefix":"10.1016","volume":"251","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0005-0369","authenticated-orcid":false,"given":"Stavros","family":"Athanasiou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Pitsouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4301-8775","authenticated-orcid":false,"given":"Themos","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Zacharakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8534-646X","authenticated-orcid":false,"given":"Maurizio","family":"Serati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2020.05.018_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/nau.20798","article-title":"An international urogynecological association (IUGA)\/ international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurol Urodyn"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0010","first-page":"71","article-title":"Review of the epidemiology of overactive bladder","volume":"8","author":"Eapen","year":"2016","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12894-015-0009-6","article-title":"Correlation between psychological stress levels and the severity of overactive bladder symptoms","volume":"15","author":"Lai","year":"2015","journal-title":"BMC Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0020","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.juro.2013.02.104","article-title":"Selective \u03b23-adrenoreceptor agonists in the treatment of overactive bladder","volume":"190","author":"Anderson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2019.02.005","article-title":"The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients with Overactive bladder who have previously been managed with an antimuscarinic: a Network Meta-analysis","author":"Lozano-Ortega","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/nau.23863","article-title":"Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder","volume":"38","author":"Wang","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1756287218781255","article-title":"The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy","volume":"10","author":"Andersson","year":"2018","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0040","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0045","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/iju.13498","article-title":"Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms\/overactive bladder: comparison with placebo and tolterodine","volume":"25","author":"Sebastianelli","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/bju.13945","article-title":"Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis","volume":"120","author":"Drake","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0055","first-page":"147","article-title":"Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency","volume":"5","author":"Lee","year":"2013","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0060","first-page":"1","article-title":"Multivariate analysis of hypertension in general US adults based on the 2017 ACC\/AHA guideline: data from the national health and nutrition examination survey 1999 to 2016","volume":"21","author":"Wang","year":"2019","journal-title":"Blood Press"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0070","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1590\/s1677-5538.ibju.2018.0518","article-title":"Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence","volume":"45","author":"Ozkidik","year":"2019","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0075","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7271289","article-title":"Does Pharmacological Treatment Reduce the Incidence of Lower Urinary Tract Symptoms (LUTS) after Transobturator Sling?","volume":"2019","author":"Rechberger","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0080","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s00345-019-02644-7","article-title":"Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and b3 adrenoceptor agonists","volume":"37","author":"Okui","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/UA.UA_70_18","article-title":"Investigation of the reasons for withdrawal from long-term treatment with mirabegron of treatment-na\u00efve Japanese female patients with overactive bladder in the real-world clinical setting","volume":"11","author":"Tanaka","year":"2019","journal-title":"Urol Ann"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0090","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000496606","article-title":"Urodynamics as a prognosticator of mirabegron treatment outcomes","volume":"84","author":"Kopp Kallner","year":"2019","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0095","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000497282","article-title":"Effects of mirabegron on anxiety and depression in female patients with overactive bladder","volume":"102","author":"Kinjo","year":"2019","journal-title":"Urol Int"},{"issue":"7","key":"10.1016\/j.ejogrb.2020.05.018_bib0100","article-title":"The impact of Mirabegron on sexual function in women with idiopathic overactive bladder","volume":"19","author":"Gubbiotti","year":"2019","journal-title":"BMC Urol"},{"issue":"61","key":"10.1016\/j.ejogrb.2020.05.018_bib0105","volume":"18","author":"Zachariou","year":"2018","journal-title":"BMC Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0110","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11255-017-1777-6","article-title":"Is it possible to cure the symptoms of the overactive bladder in women?","volume":"50","author":"Krhut","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/luts.12151","article-title":"Long-term persistence with mirabegron versus Solifenacin in women with overactive bladder: prospective, randomised trial","volume":"10","author":"Kinjo","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/luts.12167","article-title":"Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study","volume":"10","author":"Hsiao","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0125","doi-asserted-by":"crossref","DOI":"10.1002\/nau.23050","article-title":"Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: a randomized crossover study (the MICRO study)","volume":"36","author":"Torimoto","year":"2017","journal-title":"Neurol urodyn"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0130","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00192-016-3219-x","article-title":"Is mirabegron equally as effective when used as first-or-second-line therapy in women with overactive bladder?","volume":"28","author":"Serati","year":"2017","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0135","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/iju.13231","article-title":"Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: a randomized controlled trial (COMFORT study)","volume":"23","author":"Otsuka","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0140","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000445808","article-title":"Comparison of therapeutic efficacy and urodynamic findings of solifenacin succinate versus Mirabegron in women with overactive bladder syndrome: results of a randomized controlled study","volume":"97","author":"Vecchioli Scaldazza","year":"2016","journal-title":"Urol Int"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0145","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00192-016-2945-4","article-title":"Tolerability in a large, prospective case series of women prescribed mirabegron","volume":"27","author":"Duckett","year":"2016","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0150","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/GME.0000000000000708","article-title":"Hormonal influence of the effect of mirabegron treatment for overactive bladder","volume":"23","author":"Kallner","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejogrb.2016.05.048","article-title":"Safety and efficacy of mirabegron in daily clinical practice: a prospective observational study","volume":"203","author":"Kallner","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0160","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejogrb.2015.11.018","article-title":"Impact of body mass index on treatment efficacy of mirabegron for overactive bladder in females","volume":"196","author":"Krhut","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0165","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00192-015-2809-3","article-title":"Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?","volume":"27","author":"Basu","year":"2016","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0170","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.urology.2015.01.002","article-title":"Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder","volume":"85","author":"Matsukawa","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0175","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00192-009-1049-9","article-title":"Do women with overactive bladder have realistic expectations for therapy?","volume":"21","author":"Renganathan","year":"2010","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0180","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/2042098616659412","article-title":"Mirabegron in overactive Bladder patients: efficacy review and update on drug safety","volume":"7","author":"Warren","year":"2016","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0185","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.urology.2011.06.020","article-title":"Responsiveness and minimal clinically important change in overactive bladder symptom score","volume":"78","author":"Gotoh","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0190","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.juro.2006.03.088","article-title":"Determining the importance of change in the overactive bladder questionnaire","volume":"176","author":"Coyne","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0195","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jsxm.2017.05.005","article-title":"Does the severity of overactive bladder symptoms correlate with risk for female sexual dysfunction?","volume":"14","author":"Juliato","year":"2017","journal-title":"J Sex Med"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0200","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/j.1743-6109.2011.02250.x","article-title":"The impact of OAB on sexual health in men and women: results from EpiLUTS","volume":"8","author":"Coyne","year":"2011","journal-title":"J Sex Med"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0205","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.eururo.2007.11.008","article-title":"Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy","volume":"54","author":"Serati","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0210","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1743-6109.2008.00818.x","article-title":"The impact of lower urinary tract symptoms and urinary incontinence on female sexual dysfunction using a validated instrument","volume":"5","author":"Cohen","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0215","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-021889","article-title":"Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review","volume":"8","author":"Yeowell","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0220","first-page":"728","article-title":"Comparing adherence and persistence across 6 chronic medication classes","volume":"15","author":"Yeaw","year":"2009","journal-title":"JMPC"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0225","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.amjms.2016.01.010","article-title":"Medication adherence: truth and consequences","volume":"351","author":"Brown","year":"2016","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.ejogrb.2020.05.018_bib0230","first-page":"147","article-title":"Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency and frequency","author":"Lee","year":"2013","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0235","article-title":"Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo","author":"Chapple","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejogrb.2020.05.018_bib0240","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/14740338.2018.1453496","article-title":"Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder","volume":"17","author":"Rosa","year":"2018","journal-title":"Expert Opin Drug Saf"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211520302694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211520302694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:47:29Z","timestamp":1759556849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211520302694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":48,"alternative-id":["S0301211520302694"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.05.018","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mirabegron in female patients with overactive bladder syndrome: What\u2019s new? A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2020.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}